Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-23T09:56:49.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Benefits and Costs of Recombinant Human Erythropoietin for End-Stage Renal Failure: A Review: Benefits and Costs of Erythropoietin

Published online by Cambridge University Press:  10 March 2009

Paul McNamee ,
Eddy van Doorslaer  and
Rob Segaar
Paul McNamee
Affiliation:
University of Newcastle-upon-Tyne
Eddy van Doorslaer
Affiliation:
Erasmus University
Rob Segaar
Affiliation:
Erasmus University
Get access Rights & Permissions [Opens in a new window]

Abstract

Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 9 , Issue 4 , Fall 1993 , pp. 490 - 504
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Besarab, A.Recombinant human erythropoietin: Physiology, pathophysiology of anemia in renal failure and economic aspects related to dosing. American Journal of Nephrology, 1990, 10 (suppl. 2), 2–6.CrossRefGoogle ScholarPubMed
2.Bommer, J., Ritz, E., Weinreich, T., et al. Subcutaneous erythropoietin. Lancet, 1988, 2, 406.CrossRefGoogle ScholarPubMed
3.Bunn, H.Recombinant human erythropoietin therapy in cancer patients. Journal of Clinical Oncology, 1990, 8, 949–51.CrossRefGoogle ScholarPubMed
4.Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. British Medical Journal, 1990, 300, 573–78.CrossRefGoogle Scholar
5.Casati, S., Campise, M., & Crepaldi, M.Hemodialysis efficiency after long term treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation, 1989, 4, 718–20.CrossRefGoogle ScholarPubMed
6.Casati, S., Passerini, P., Campise, M., et al. Benefits and risk of protracted treatment with recombinant human erythropoietin in patients having hemodialysis. British Medical Journal, 1987, 295, 1017–20.CrossRefGoogle Scholar
7.Churchill, D., Taylor, D., Cook, R., et al. Canadian hemodialysis morbidity study. American Journal of Kidney Diseases, 1992, 19(3), 214–34.CrossRefGoogle ScholarPubMed
8.Erslev, A.Erythropoietin. New England Journal of Medicine, 1991, 324, 1339–44.CrossRefGoogle ScholarPubMed
9.Eschbach, J., Abdulhadi, M., Browne, J., et al. Recombinant human erythropoietin in anemic patients with end-stage renal failure: Results of a phase III multi-center clinical trial. Annals of Internal Medicine, 1989, 111, 992–1000.CrossRefGoogle Scholar
10.Eschbach, J., Egrie, J., Downing, M., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin — results of a combined phase I and II clinical trial. New England Journal of Medicine, 1987, 316, 73–78.CrossRefGoogle ScholarPubMed
11.European Dialysis and Transplant Association (EDTA). Combined report on regular dialysis and transplantation in Europe, XX, 1989. Nephrology Dialysis Transplantation, 1991, 6 (suppl. 1), 20–21.Google Scholar
12.Evans, R., Manninen, D., & Garrison, L.The quality of life of patients with end-stage renal disease. New England Journal of Medicine, 1985, 312, 553–59.CrossRefGoogle ScholarPubMed
13.Evans, R., & Rader, B.The quality of life of hemodialysis patients receiving recombina human erythropoietin: A comparative analysis. Seattle: Batelle Human Affairs Researc Centers, 1989. (Edited version: Journal of the American Medical Association, 1990, 263, 825–30.Google Scholar
14.Fischl, M., Galpin, S., Levine, J., et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. New England Journal of Medicine, 1990, 322, 1488–93.CrossRefGoogle ScholarPubMed
15.Gabriel, R.Wanted: funds for a treatment that really works. British Medical Journal, 1989, 298, 64.Google Scholar
16.Gafni, A., & Birch, S.Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal, 1993, 148(6), 913–17.Google ScholarPubMed
17.Haley, N., Davidson, R., Eschbach, J., et al. Patterns of development of hypertension with recombinant human erythropoietin therapy. American Journal of Hypertension, 1989, 2 (suppl. 56A).Google Scholar
18.Halperin, D., Wacker, P., Lacourt, G., et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. Journal of Pediatrics, 1990, 116, 779–86.CrossRefGoogle ScholarPubMed
19.Keown, P.The highly sensitized patient: Etiology, impact and management. Transplantation Proceedings, 1987, 19, 74–78.Google ScholarPubMed
20.Keown, P.Recombinant erythropoietin and renal transplantation. Seminars in Nephrology, 1990, 10 (Suppl. 1), 52–58.Google ScholarPubMed
21.Laupacis, A., Feeny, D., Detsky, A., & Tugwell, P.How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992, 146, 473–81.Google ScholarPubMed
22.Laupacis, A., Feeny, D., Detsky, A., & Tugwell, P.Tentative guidelines for using clinical and economic evaluations revisited. Canadian Medical Association Journal, 1993, 148(6), 927–29.Google ScholarPubMed
23.Leese, B., Hutton, J., &Maynard, A. (eds.) The costs and benefits of the use of erythropoietin in the treatment of anemia arising from chronic renal failure: A European study. York: Centre for Health Economics Occasional Paper, 1990.Google Scholar
24.Levy, D., Garrison, R., Savage, D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. New England Journal of Medicine, 1990, 322, 1567–71.CrossRefGoogle ScholarPubMed
25.Lundin, A.Quality of life: Subjective and objective improvements with recombinant erythropoietin. Seminars in Nephrology, 1989, 9 (suppl. 1), 22–29.Google Scholar
26.Macdougall, I., Hutton, R., Cavill, I., et al. Treating renal anemia with recombinant human erythropoietin: Practical guidelines and a clinical algorithm. British Medical Journal, 1990, 300, 655–59.CrossRefGoogle ScholarPubMed
27.McMahon, L., & Dawborn, J.Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. American Journal of Nephrology, 1990, 10, 404–08.CrossRefGoogle ScholarPubMed
28.Mohide, E., Torrance, G., Streiner, D., et al. Measuring the well-being of family caregivers using the time trade-off technique. Clinical Epidemiology, 1988, 41, 475–82.CrossRefGoogle ScholarPubMed
29.Naylor, C., Williams, J., Basinski, A., & Goel, V.Technology assessment and cost effectiveness analysis: misguided guidelines? Canadian Medical Association Journal, 1993, 148(6), 921–24.Google ScholarPubMed
30.Opelz, G., Graver, B., Mickey, M., et al. Lymphocytoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation, 1981, 32, 177–83.CrossRefGoogle Scholar
31.Opelz, G., & Terasaki, P.Improvement of kidney graft survival with increased numbers of blood transfusions. New England Journal of Medicine, 1978, 299, 799–803.CrossRefGoogle ScholarPubMed
32.Phelan, D., Hibbett, S., Wetter, L., et al. Recombinant erythropoietin: Does it really affect sensitization? Transplantation Proceedings, 1991, 23, 409–10.Google Scholar
33.Pincus, T., Olsen, N., Russell, I., et al. Multi-center study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. American Journal of Medicine, 1990, 89, 161–68.CrossRefGoogle Scholar
34.Raine, A.Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implications for erythropoietin therapy. Lancet, 1988, 1, 97–100.CrossRefGoogle ScholarPubMed
35.Sheingold, S., Churchill, D., Muirhead, N., & Laupacis, A.Recombinant human erythropoietin: Factors to consider in cost-benefit analysis. American Journal of Kidney Diseases, 1991, 17, 86–92.CrossRefGoogle ScholarPubMed
36.Sheingold, S., Churchill, D., Muirhead, N., et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Social Science and Medicine, 1992, 34, 983–91.CrossRefGoogle ScholarPubMed
37.Silberberg, J., Racine, N., Barre, P., Sniderman, A.Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Canadian Journal of Cardiology, 1990, 6, 1–4.Google ScholarPubMed
38.Sobota, J.Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. Contributions in Nephrology, 1989, 76, 166–78.CrossRefGoogle ScholarPubMed
39.Spivak, J.Application of recombinant human erythropoietin in oncology. Cancer Investigation, 1990, 8, 301–02.CrossRefGoogle ScholarPubMed
40.Stevens, M., Summerfield, G., Hall, A., et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end-stage renal disease. British Medical Journal, 1992, 304, 474–77.CrossRefGoogle ScholarPubMed
41.Stewart, W.Erythropoietin—trials then tribulation. Scottish Medical Journal, 1990, 36, 3–4.CrossRefGoogle Scholar
42.Stockman, J.Erythropoietin: Off again, on again. Journal of Pediatrics, 1988, 112, 906–08.CrossRefGoogle ScholarPubMed
43.Sundal, E., & Kaeser, R.Correction of anemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year’s treatment in a European multicenter study of 150 hemodialysis-dependent patients. Nephrology Dialysis Transplantation, 1989, 4, 979–87.CrossRefGoogle Scholar
44.Thomas, M., Saker, B., Thatcher, G., et al. Cost-effectiveness of weekly and fortnightly subcutaneous erythropoietin. Lancet, 1990, 2, 1533–34.CrossRefGoogle Scholar
45.Vreugdenhil, G., & Swaak, A.Anemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment. Rheumatology International, 1990, 9, 243–57.CrossRefGoogle ScholarPubMed
46.Vreugdenhil, G.,Wognum, A., van Eijk, H. & Swaak, A.Anemia in rheumatoid arthritis: the role of iron, vitamin B12, folic acid deficiency and erythropoietin responsiveness. Annals of the Rheumatic Diseases, 1990, 49, 93–98.CrossRefGoogle ScholarPubMed
47.Ward, H.Implications of recombinant erythropoietin therapy for renal transplantation. American Journal of Nephrology, 1990, 10 (suppl. 2), 44–52.CrossRefGoogle ScholarPubMed
48.Watson, A.Adverse effects of therapy for the correction of anemia in hemodialysis patients. Seminars in Nephrology, 1989, 9 (suppl. 1), 30–34.Google ScholarPubMed
49.Winearls, C., Oliver, D., Pippard, M., et al. Effects of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet, 1986, 2, 1175–78.CrossRefGoogle Scholar